.jpg)
1 hour ago
2
Article content
Telehealth provider Hims & Hers Health Inc. announced Thursday the availability of generic semaglutide through its platform, allowing eligible Canadians access to digital prescriptions for the popular drug widely used for weight loss.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
With Health Canada’s approval of the first two generic injection semaglutide, the medication popularized by the brand name Ozempic, Canadians can now access a more affordable version of the drug prescribed in the treatment of type 2 diabetes but widely used off-label as an anti-obesity medication.
Article content
Article content
Article content
Hims & Hers has started offering eligible customers personalized treatment plans starting at $149/month, which would include the medication.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Generic medication will be more affordable than other options, and I think that will be a particularly attractive opportunity for Canadians,” Austin Kouri, general manager of Hims & Hers Canada, said in an interview. “This is obviously a little bit of an unprecedented environment, with Canada being one of the first to bring generics in the market.”
Article content
Canada is the first in the G7 to have an approved generic version of semaglutide, following Health Canada‘s approval of one made by Indian pharmaceutical company Dr. Reddy’s Laboratories on April 28 and a second one from Canadian pharmaceutical giant Apotex Inc. on May 1.
Article content
Health Canada is also reviewing seven other submissions for generic semaglutides by different companies, it said. These include Ozempic-maker Novo Nordisk’s second brands Plosbrio (similar to Ozempic) and Poviztra (similar to Wegovy), which the Danish company said were filed to “maintain flexibility,” although it has not made any decisions to launch the products.
Article content
Hims & Hers will be offering Apotex’s Apo-semaglutide injection, the generic equivalent of Ozempic launched earlier this month.
Article content
Apotex said the product is shipping this week to wholesalers and distributors nationally, and should be available to Canadians at their local pharmacies by the end of this week or early next.
Article content
English (US)